Raxibacumab: potential role in the treatment of inhalational anthrax
about
Alternative pre-approved and novel therapies for the treatment of anthraxAntitoxin Treatment of Inhalation Anthrax: A Systematic ReviewRevisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for AnthraxEfficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthraxPassive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal AnthraxTechnological Microbiology: Development and ApplicationsGeneration and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.Bactericidal monoclonal antibodies specific to the lipopolysaccharide O antigen from multidrug-resistant Escherichia coli clone ST131-O25b:H4 elicit protection in mice.An overview of the lagomorph immune system and its genetic diversity.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy.Evolution of phage display technology: from discovery to application.Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid DiagnosticsAn assessment of the future impact of alternative technologies on antibiotics markets.Phage display-derived human antibodies in clinical development and therapyAnthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support.Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against Bacillus anthracis Sterne strain.Self-defense against Bacillus anthracis toxins: Is P-selectin the key?The wide utility of rabbits as models of human diseases.
P2860
Q28075453-8A62EC98-256C-4D7A-B273-3623D54EE50DQ28383765-85A6098C-B7BF-4CED-AA7A-030CAECA4EA7Q28384806-A6E48C8E-1F1F-438D-9245-1B1E3FA17D18Q28389738-E3558317-5B3C-467C-BB99-1B3B62E00CA1Q28392599-D68F261F-F285-4E62-AA79-185803C47380Q30250972-7DB8C6C7-0BC5-484B-BDC4-0E28CB8F11DFQ35548062-82573FF4-D93E-478F-87C7-FAF7303B77E9Q35607916-7A3BC54C-846E-44F2-8704-450EB40EB842Q35785529-4359713B-5B7A-4D04-9D5D-FF1B82F99D19Q36023082-1D006762-A6E5-4DC6-81FE-507656EA13C9Q36033286-C83DBB01-4EFB-405E-98B5-E5E367FC938CQ36183954-FBB20D48-A79C-4726-92D3-CFD9FCF69746Q37087480-7962E5DD-1939-434A-BF89-DC38E8419AA7Q37367183-431A7408-F70D-4157-B7A2-3AE35CDDBC55Q41416393-578B9C5E-49F0-413D-92DA-48DC9408DA1CQ45894703-7027C70B-6363-46BF-AD36-D4D508872D0CQ47135050-B45E3DB6-B528-46F0-B52E-A765AC2D7DAFQ48140013-C98944B3-C2D2-4751-B396-1795A6AA6BB7Q55250836-B08E8574-D2B2-4F4A-A85E-C7FB6110A24B
P2860
Raxibacumab: potential role in the treatment of inhalational anthrax
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Raxibacumab: potential role in the treatment of inhalational anthrax
@en
type
label
Raxibacumab: potential role in the treatment of inhalational anthrax
@en
prefLabel
Raxibacumab: potential role in the treatment of inhalational anthrax
@en
P2860
P356
P1476
Raxibacumab: potential role in the treatment of inhalational anthrax
@en
P2093
Carlos E Kummerfeldt
P2860
P304
P356
10.2147/IDR.S47305
P407
P577
2014-04-29T00:00:00Z